The aim of this study was to compare the usefulness of primary angioplasty only to culprit vessel versus complete revascularization guided by fractional flow reserve (FFR) in patients admitted pursuing an acute myocardial infarction with ST-segment elevation and have multiple injuries vessels. After a successful primary angioplasty to culprit artery, patients were randomized 1:1 to<a href="https://solaci.org/en/2015/06/24/danami3-primary-angioplasty-to-culprit-vessel-versus-multivessel-guided-by-ffr/" title="Read more" >...</a>

Current guidelines suggest treating only the culprit artery of myocardial infarction with ST-segment elevation. This prospective and randomized work included 296 patients in 7 centers suffering ST-segment elevation acute myocardial infarction referred for primary angioplasty randomized to treat only the culprit artery (n = 146) versus complete revascularization (n = 150).&nbsp; In the culprit artery<a href="https://solaci.org/en/2015/06/24/culprit-complete-revascularization-versus-culprit-artery-of-infarct-only/" title="Read more" >...</a>

Previous studies suggest the excellent performance of the bioactive coated stent TITAN 2 compared with drug-eluting stents (DES). The aim of the study was to evaluate the results of this device in patients undergoing both ST segment elevation and without ST segment elevation acute coronary syndrome. A total of 1066 patients were included, of whom<a href="https://solaci.org/en/2015/06/24/titan-ami-final-results-of-bio-active-coated-stent/" title="Read more" >...</a>

Spanish-Portuguese multicentre CIBELES study (Raul Moreno, Madrid, Spain) compared two drug-eluting stents &#8211; an everolimus (Xience V, Abbott Vascular, USA) and a sirolimus-releasing eluting stent (Cypher Select, Cordis Corporation, Miami Lakes, Florida, USA) in the context of total chronic coronary occlusions. With a non-inferiority design, the study randomized 208 patients (1:1), using as the primary<a href="https://solaci.org/en/2015/06/24/cibeles-xience-v-comparative-study-vs-cypher-for-the-treatment-of-total-chronic-occlusions/" title="Read more" >...</a>

Randomized prospective study comparing the everolimus-eluting polymer-coated stent versus a biodegradable polymer with biolimus coated stent.&nbsp; While the use of first generation DES effectively reduces restenosis and reintervention rates, several meta-analyzes have shown a higher rate of late events of thrombotic origin associated with inflammatory phenomena and delayed reendothelialization at the site of implantation compared<a href="https://solaci.org/en/2015/06/24/compare-ii-a-randomized-prospective-study-compared-the-permanent-polymer-everolimus-eluting-stent-with-a-biodegradable-polymer-biolimus-coated-stent/" title="Read more" >...</a>

Fundamentals. Background: Although we&#8217;ve had more than a decade of experience with implanting drug-eluting stents, (DES), the best treatment for restenosis on these devices remains unknown. The drug-eluting balloons are a promising alternative which avoid the possibility of a new layer of metal on the restenotic injury. This study compared the performance of these balls<a href="https://solaci.org/en/2015/06/24/isar-desire-3-a-paclitaxel-eluting-balloon-versus-taxus-in-the-treatment-of-eluting-stent-restenosis/" title="Read more" >...</a>

Previous studies of non-inferiority (SORT-OUT III and V) compared the biodegradable polymer biolimus-eluting stent (BES) with permanent polymer stent and sirolimus-eluting stent (SES) or everolimus-eluting stent (EES), showing no differences, although the data is still contradictory. The aim of this study was to evaluate whether the recently approved BES is not inferior to EES in<a href="https://solaci.org/en/2015/06/24/next-trial-looked-at-a-non-inferiority-degradable-polymer-stent-versus-a-second-generation-permanent-polymer-stent/" title="Read more" >...</a>

There is still concern about the safety of drug-eluting stents (DES) due to the possibility of late and very late thrombosis. Dual antiplatelet aggregation for a year is recommended for patients receiving DES. The objective of this study was to test the non-inferiority of a new drug-eluting stent in terms of endothelial coverage after 3<a href="https://solaci.org/en/2015/06/24/demonstr8-better-endothelial-coverage-by-oct-for-the-new-des/" title="Read more" >...</a>